News

Sugarcane waste could be a key ingredient in tackling plastic pollution, with an AIBN researcher receiving funding to turn the green waste into sustainable packaging.

AIBN researcher Associate Professor Jessica Mar has received a 2020 Georgina Sweet Award for Women in Quantitative Biomedical Science. The award was given to Assoc Professor Mar for both Excellence in Research and Excellence in Inclusivity.

A startup company developing technology based on University of Queensland (UQ) research has announced it will partner with the US Government to test its needle-free vaccine delivery technology.

AIBN's Professor Kristofer Thurecht and IMB's Professor Robert Parton and are Eureka Prize finalists for their project using VR to solve the problem of visualising complex data.

A healthy gut might be impacting the longevity of people living with Motor Neurone Disease (MND), according to new research from The University of Queensland.

A call to arms has gone out to Queenslanders aged 56 and over to help advance The University of Queensland’s COVID-19 vaccine project.

Pre-clinical testing of The University of Queensland’s COVID-19 vaccine, developed in AIBN labs has produced positive indications about its potential effectiveness and manufacturability.

Most diagnostic methods use costly materials and are time-consuming and expensive to run, but PhD candidate Mostafa Masud and research supervisors Professor Yusuke Yamauchi and Dr MD Shahriar Hossain have developed a cheaper, faster and ultrasensitive biosensor for point-of-care testing.

Researchers at the National Biologics Facility (NBF) at The University of Queensland will benefit from a substantial funding boost for COVID-19 research.

Congratulations to our 2020 AIBN Graduates 

Even before being awarded her PhD at the University of Queensland, Yun (Amy) Liu’s research had reached stratospheric heights.

The next critical phase for The University of Queensland’s COVID-19 vaccine, is underway – with the research effort moving out of the lab and into human trials. The vaccine has been developed by Professor Paul Young, Associate Professor Keith Chappell and Dr Dan Watterson who have been driving the program, housed at AIBN, jointly with Project Director, AIBN’s Professor Trent Munro.

A novel rapid cancer diagnostic technology with the potential to quickly and easily detect cancer has been licensed for further development.

The UQ vaccine uses the ‘molecular clamp’ technology developed by Professor Paul Young, Associate Professor Keith Chappell and Dr Dan Watterson who have been driving the program, housed at AIBN, jointly with Project Director, AIBN’s Professor Trent Munro.

Australian Institute for Bioengineering and Nanotechnology research has helped attract partnership that could revolutionise the manufacture and delivery of vaccines.

AIBN researchers have secured new funding to help the design of new nanomedicines, diagnostics and strengthen collaborative industry-partnered research projects.

AIBN researchers will help develop early and improved diagnostic tests to lift ovarian cancer survival rates with funding from the Medical Research Future Fund.

AIBN Director Professor Alan Rowan has been elected to the Australian Academy of Science.

A new program that aims to significantly improve supercapacitors will proceed after securing international backing.

AIBN researchers have developed a new way to produce nanoparticles that carry much higher drug concentrations.